Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Harrow, Inc. (NASDAQ:HROW) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $71.4286.

HROW has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $94.00 price objective on shares of Harrow in a report on Tuesday, November 11th. HC Wainwright raised their price target on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Zacks Research upgraded shares of Harrow from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Finally, LADENBURG THALM/SH SH raised their target price on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th.

Hedge Funds Weigh In On Harrow

A number of institutional investors and hedge funds have recently modified their holdings of the company. Pictet Asset Management Holding SA bought a new stake in shares of Harrow in the fourth quarter worth $248,000. UBS Group AG boosted its position in Harrow by 82.0% in the fourth quarter. UBS Group AG now owns 222,362 shares of the company’s stock worth $10,896,000 after purchasing an additional 100,160 shares during the last quarter. Vanguard Group Inc. boosted its position in Harrow by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after purchasing an additional 50,889 shares during the last quarter. Walleye Partners LLC bought a new stake in shares of Harrow during the 4th quarter valued at about $660,000. Finally, Round Rock Advisors LLC increased its position in shares of Harrow by 67.7% during the 4th quarter. Round Rock Advisors LLC now owns 17,412 shares of the company’s stock valued at $853,000 after purchasing an additional 7,027 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Trading Down 1.5%

NASDAQ HROW opened at $41.93 on Friday. Harrow has a 12 month low of $20.85 and a 12 month high of $54.85. The company has a current ratio of 2.72, a quick ratio of 2.52 and a debt-to-equity ratio of 5.21. The stock’s fifty day moving average price is $46.56 and its 200-day moving average price is $41.48. The stock has a market cap of $1.55 billion, a P/E ratio of -419.26 and a beta of 0.02.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The company had revenue of $71.64 million during the quarter, compared to analyst estimates of $73.70 million. As a group, equities analysts forecast that Harrow will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.